Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

205 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, Ralston SH, Walters M, Robertson M, De Caterina R, Findlay E, Perez-Ruiz F, McMurray JJV, MacDonald TM; FAST Study Group. Mackenzie IS, et al. Among authors: nuki g. Lancet. 2020 Nov 28;396(10264):1745-1757. doi: 10.1016/S0140-6736(20)32234-0. Epub 2020 Nov 9. Lancet. 2020. PMID: 33181081 Free article. Clinical Trial.
Up-titration of allopurinol in patients with gout.
Jennings CG, Mackenzie IS, Flynn R, Ford I, Nuki G, De Caterina R, Riches PL, Ralston SH, MacDonald TM; FAST study group. Jennings CG, et al. Among authors: nuki g. Semin Arthritis Rheum. 2014 Aug;44(1):25-30. doi: 10.1016/j.semarthrit.2014.01.004. Epub 2014 Jan 23. Semin Arthritis Rheum. 2014. PMID: 24560169
Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia.
MacDonald TM, Ford I, Nuki G, Mackenzie IS, De Caterina R, Findlay E, Hallas J, Hawkey CJ, Ralston S, Walters M, Webster J, McMurray J, Perez Ruiz F, Jennings CG; Members of the FAST Study Group. MacDonald TM, et al. Among authors: nuki g. BMJ Open. 2014 Jul 10;4(7):e005354. doi: 10.1136/bmjopen-2014-005354. BMJ Open. 2014. PMID: 25011991 Free PMC article. Clinical Trial.
Changing paradigms in the management of gout.
Nuki G, Riches P. Nuki G, et al. J R Coll Physicians Edinb. 2020 Jun;50(2):124-132. doi: 10.4997/JRCPE.2020.209. J R Coll Physicians Edinb. 2020. PMID: 32568281 Review.
Cardiovascular safety of febuxostat - Authors' reply.
MacDonald TM, Nuki G, Robertson M, Ford I, Mackenzie IS. MacDonald TM, et al. Among authors: nuki g. Lancet. 2021 Sep 11;398(10304):955-956. doi: 10.1016/S0140-6736(21)01383-0. Lancet. 2021. PMID: 34509228 No abstract available.
Improving cardiovascular and renal outcomes in gout: what should we target?
Richette P, Perez-Ruiz F, Doherty M, Jansen TL, Nuki G, Pascual E, Punzi L, So AK, Bardin T. Richette P, et al. Among authors: nuki g. Nat Rev Rheumatol. 2014 Nov;10(11):654-61. doi: 10.1038/nrrheum.2014.124. Epub 2014 Aug 19. Nat Rev Rheumatol. 2014. PMID: 25136785 Review.
Gout: why is this curable disease so seldom cured?
Doherty M, Jansen TL, Nuki G, Pascual E, Perez-Ruiz F, Punzi L, So AK, Bardin T. Doherty M, et al. Among authors: nuki g. Ann Rheum Dis. 2012 Nov;71(11):1765-70. doi: 10.1136/annrheumdis-2012-201687. Epub 2012 Aug 3. Ann Rheum Dis. 2012. PMID: 22863577 Review.
Cost-effectiveness of febuxostat in chronic gout.
Beard SM, von Scheele BG, Nuki G, Pearson IV. Beard SM, et al. Among authors: nuki g. Eur J Health Econ. 2014 Jun;15(5):453-63. doi: 10.1007/s10198-013-0486-z. Epub 2013 May 30. Eur J Health Econ. 2014. PMID: 23719971
205 results